置信区间
动脉粥样硬化性心血管疾病
医学
队列
人口
校准
队列研究
相对风险
内科学
绝对风险降低
疾病
前瞻性队列研究
弗雷明翰风险评分
人口学
环境卫生
风险评估
统计
数学
社会学
计算机科学
计算机安全
作者
Fangchao Liu,Jianxin Li,Jichun Chen,Dongsheng Hu,Ying Li,Jianfeng Huang,Xiaoqing Liu,Xueli Yang,Jie Cao,Chong Shen,Li Wang,Zhendong Liu,Xianping Wu,Liancheng Zhao,Xigui Wu,Dongfeng Gu,Xiangfeng Lu
标识
DOI:10.1016/j.scib.2018.05.020
摘要
Evidence on the lifetime risk for atherosclerotic cardiovascular disease (ASCVD) is insufficient; yet, estimating an individual's lifetime risk allows for a comprehensive assessment of ASCVD burden. We developed and validated lifetime risk prediction equations for ASCVD using four large and ongoing prospective cohorts of Chinese, the China-PAR project (Prediction for ASCVD Risk in China). Sex-specific equations were developed using two cohorts (as the derivation cohort) of 21,320 participants. Two other independent cohorts with 14,123 and 70,838 participants were used for their external validation, respectively. We evaluated both calibration and discrimination measures for model performance. Furthermore, we estimated ASCVD-free years lost or excess absolute risk attributable to high 10-year risk (≥10.0%) and/or high lifetime risk (≥32.8%). After 12.3 years' follow-up of the derivation cohort, 1048 ASCVD events and 1304 non-ASCVD deaths were identified. Our sex-specific equations had good internal validation, with discriminant C statistics of 0.776 (95% confidence interval [CI]: 0.757-0.794) and 0.801 (95% CI: 0.778-0.825), and calibration χ2 of 9.2 (P = 0.418) and 5.6 (P = 0.777) for men and women, respectively. Good external validation was also demonstrated with predicted rates closely matched to the observed ones. Compared with men having both low 10-year and low lifetime risk, men would develop ASCVD 3.0, 4.6 and 8.6 years earlier if they had high 10-year risk alone, high lifetime risk alone, or both high 10-year and high lifetime risk at the index age of 35 years, respectively. We developed well-performed lifetime risk prediction equations that will help to identify those with the greatest potential to avert ASCVD burden after implementation of innovative clinical and public health interventions in China.
科研通智能强力驱动
Strongly Powered by AbleSci AI